Genenta Science S.p.A. is an Italian clinical-stage biotechnology company developing hematopoietic stem cell gene therapies targeting solid tumors. The company's approach involves engineering stem cells to deliver immunomodulatory molecules directly to tumor sites via infiltrating monocytes and macrophages. This platform strategy aims to overcome barriers associated with systemic delivery of immunotherapeutic agents.
The company's lead product candidate, Temferon, is in Phase 1/2a clinical development for glioblastoma multiforme in patients with unmethylated MGMT gene promoter status. Beyond glioblastoma, Genenta is evaluating Temferon for additional solid tumor indications including locally advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The company is incorporated and headquartered in Milan, Italy, with a small operational scale of 13 full-time employees. As a clinical-stage asset company, Genenta has no established revenue streams and relies on capital financing to fund development activities.
No 10-K filings found.